PRESS RELEASE REGULATED INFORMATION 26 MARCH 2015, 6:00 AM CET

Transcription

1 CARDIO3 BIOSCIENCES REPORTS 2014 FINANCIAL AND OPERATING RESULTS Significant Progress Made in Building a Global Specialty Therapeutics Company Conference Call to Be Held on 26 March 2015 at 2.00 p.m. CET / 9.00 a.m. ET Expansion into the CAR T-cell space with rapid development goals leveraging our cell therapy expertise Completed enrollment of CHART-1 with top line data in 2016, progressing towards a CHART-2 start in the USA Improved financial position following successful capital raises to finance growth Establishing our US operations in Rochester MN, and Boston MA Mont-Saint-Guibert, Belgium, Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of engineered cell-therapy treatments, today provided an update on recent business developments and strategic initiatives, and reported consolidated financial results for the twelve-month period ended 31 December 2014, prepared in accordance with IFRS. Commenting on the 2014 results, Dr Christian Homsy, CEO of Cardio3 BioSciences, said: We made significant strategic, operational and financial advancements in 2014 as we seek to build C3BS into a global specialty therapeutics company. The momentum built over this period has carried over into the early part of 2015, which has seen us reach important milestones in both of our C-Cure Phase III programs CHART-1 and CHART-2. C3BS continues to make strong progress in the late stages of C-Cure development and we look forward to reporting the upcoming futility data. Our acquisition of the OnCyte CAR T-Cell portfolio in early 2015 heralds the first major step in our strategy to leverage our unique expertise in cell therapies and drug development to expand beyond the cardiac arena to develop breakthrough treatments to change the outcome of disease. We are excited to be expanding our product offering into the prominent area of immuno-oncology and anticipate the initiation of the Phase I trial of our lead immuno-oncology candidate, CAR-NKG2D in the first half of 2015 and look forward to sharing details of our progress as we evaluate its clinical potential. We intend to leverage our cell therapy know-how and infrastructure to quickly progress those assets into later stage clinical trials in 2016, aiming at more than five trials in liquid and solid tumors in the USA and Europe. Overall, 2014 was an exciting and successful year for C3BS, but more importantly, it set the stage for even greater accomplishments in the years to come.

2 Conference call details A conference call will be held on Thursday, March 26, 2015 at 2:00 p.m. CET / 9:00 a.m. EDT to review the financial results. Christian Homsy, Chief Executive Officer, and Patrick Jeanmart, Chief Financial Officer will deliver a brief presentation, which will be available to download from here 15 minutes before the call commences, followed by a Q&A session. Participants are asked to call the assigned number approximately five minutes before the conference call begins. The call can be accessed by dialing the numbers below and quoting conference ID Participant International Dial-In + 44 (0) Belgium France United States A recording of the presentation will be available on the Cardio3 Biosciences website following the call for a period of 15 days.

3 2014 and recent operational highlights Completed enrollment in CHART-1 Phase III clinical trial of lead product candidate, C-Cure, for the treatment of ischemic heart failure, futility data expected to be reported in the second quarter of 2015 Received product-specific pediatric waiver for C-Cure from European Medicines Agency (EMA) confirming focus on adult population Initiated sites for second Phase III trial evaluating C-Cure, CHART-2, in the U.S. with new protocol for use of injection catheter C-Cath ez to deliver C-Cure, currently under review by the FDA; pending FDA clearance to initiate the trial expected in the second half of 2015 Took first major step in strategy to broaden Company s focus beyond cardiology and entered immuno-oncology arena with acquisition of OnCyte CAR T-cell portfolio from Celdara Medical, LLC Initiation of U.S. Phase I trial evaluating lead oncology candidate, CAR-NKG2D, expected in the first half of 2015 with interim results expected to be reported at various times during the trial and full data readout expected in the middle of 2016 Expanded collaboration with Mayo Clinic, through non-exclusive preferred access agreement, allowing C3BS to regularly review Mayo Clinic s regenerative medicine portfolio to identify projects of mutual interest Confirmed plans to build a new U.S.-based manufacturing facility in Rochester, Minnesota, to support the Company s current and anticipated manufacturing needs in the United States for C-Cure CHART-2, and CAR T-cell therapies portfolio, and establish a Boston based U.S. headquarters Strengthened management team to support Company in its ambitions to become a global leader in specialty therapeutics and reinforce its position in both cardiology and oncology with the appointment of Dr. Georges Rawadi as Vice President, Business Development and Dr. Warren Sherman as Chief Medical Officer 2014 and recent financial highlights Completed a 32 million private placement with U.S. and European investors at per share in February 2015, representing no discount to previous day market price and a 4% premium to the last 30 days average price preceding the transaction Completed a share capital increase of 25 million in June 2014 at 44 per share, a 14% premium to the 30 days average price preceding the transaction Completed a secondary placement of 141,800 shares at 43.5 per share with six new Swiss institutional investors in July This transaction occurred off-market through an exchange of shares between certain historical shareholders of the Company and Swiss professional investors.

4 30 million in cash and term deposits as of 31 December 2014, sufficient to fund the C-Cure clinical program until the availability of the read-out of the primary endpoint, anticipated first half of Operational review C-Cure clinical program update CHART-1 (Congestive Heart failure Cardiopoietic Regenerative Therapy) Trial CHART-1 is a Phase III clinical trial evaluating C-Cure, the Company s lead cardiac product candidate. The Company successfully met its defined objective of enrolling the 240 th patient in CHART-1 by the end of 2014 and completed patient enrolment in March At the beginning of May, the European Medicines Agency (EMA) issued a certification of quality data for C-Cure. The Advanced Therapy Medicinal Products (ATMP) certification recognizes the data generated for C-Cure in its development program so far as meeting the standards imposed by t he EMA. The ATMP s certification for quality data will facilitate the EMA s review of the Company s anticipated f uture application for marketing authorization for C-Cure. In mid-september, Cardio3 BioSciences announced it had received the unanimous recommendation of the Data Safety and Monitoring Board (DSMB) to continue the CHART-1 trial according to the original protocol. The recommendation was based on a planned analysis performed on all patient safety data available as per mid-august All the members of the DSMB approved the continuation of the trial having concluded that one month post treatment, C-Cure and C-Cath ez showed no safety issues that compromise the continuation of the CHART-1 Phase III study. The Company anticipates publication of the full data set for CHART-1 in mid However, the Company expects to be able to publish the interim futility data from the CHART-1 trial in the second quarter of These data, will be independently assessed by the trial s Data and Safety Management Board (DSMB), which will assess whether efficacy indicators have been met and whether the clinical study can be further completed. CHART-2 In January 2014, the U.S. Food and Drug Administration (FDA) authorized the Company's Investigational New Drug (IND) application for clinical testing of C-Cure as a treatment targeting heart failure using the MyoStar injection catheter. CHART-2, the Company's second Phase III clinical trial to be conducted in the United States, is intended to assess the efficacy of C-Cure. The primary endpoint of the trial is the

5 Six Minute Walk Test nine months post-procedure, a commonly used index of cardiovascular performance. Results of the Phase II trial demonstrated that C-Cure showed a 25% relative improvement in cardiac function over baseline for treated patients versus 0.7% relative improvement for the control group. In November, Cardio3 BioSciences announced the nomination of its three Co-principal investigators for its CHART-2 Phase III clinical trial of C-Cure : Dr Bernard J. Gersh, Professor of Medicine at Mayo Clinic College of Medicine, Rochester, Minnesota; Dr Thomas Povsic, Associate Professor of Medicine at Duke University, Durham, North Carolina; and Dr Gerasimos Filippatos, Head of the Heart Failure Unit at the Athens University Hospital Attikon, President of the Heart Failure Association of the European Society of Cardiology (ESC). In January 2015, Cardio3 BioSciences submitted an amendment to the protocol to the FDA for the CHART-2 study which included the use of the injection catheter C-Cath ez alongside C-Cure in the Phase III trial. Final review and FDA decision are expected in the second half of2015. C-Cure Pediatric Investigation Plan waiver In March 2014 Cardio3 BioSciences received from the EMA an official, product-specific pediatric waiver for C-Cure across all subsets of the pediatric population for the treatment of ischemic heart disease. As medical and surgical treatments exist for this extremely rare condition among pediatric patients, Cardio3 BioSciences has focused its regulatory approach for C-Cure regenerative therapy on the adult patient population. Subsequently, the EMA delivered the waiver to Cardio3 BioSciences, hence making it official that the clinical studies of C-Cure would be restricted to the adult population. Publication in specialized press During the first quarter of 2014, Cardio3 BioSciences lineage-specified cardiac progenitor (Cardiopoietic) technology was referenced in the journal Nature Reviews Cardiology and European Heart Journal as a next generation advancement in the science of regeneration. Strengthening of Company assets and development strategy In January 2015, Cardio3 BioSciences entered the immuno-oncology space through the acquisition of OnCyte s CAR T-Cell portfolio of clinical-stage immuno-oncology assets. The portfolio includes three autologous CAR T-Cell cell therapy products and an allogeneic T-Cell platform, targeting a broad range of cancer indications. CAR T-Cell immuno-oncology represents one of the most promising cancer treatment areas today. We expect to initiate a U.S. Phase I trial evaluating our lead immune-oncology portfolio candidate, CAR-NKG2D, in the first quarter of 2015, with interim results expected at various times during

6 the trial and final results expected by mid The Company intends to rapidly advance the development all of the OnCyte assets, with a focus on CAR NKG2D, which should move into at least five later stage trials in 2016, in various solid and liquid tumors in both Europe and the USA. In October 2014, Cardio3 BioSciences announced the signing of a non-exclusive preferred access agreement with the Mayo Clinic. With this agreement, Cardio3 BioSciences agreed to give preferred consideration for Rochester, Minnesota to the U.S. to build a manufacturing facility for the production of C-Cure, at a facility located adjacent to the campus of the Mayo Clinic, and the Mayo Clinic agreed to periodically review with Cardio3 BioSciences its portfolio of regenerative medicine technologies, including in the areas of cardiology and oncology, with a view towards future potential licensing. Building on its core competencies and unique expertise in cellular therapies and cardiovascular diseases developed with C-Cure, Cardio3 Biosciences potential access to Mayo Clinic Center for Regenerative Medicine technologies has the potential to further strengthen the Company s long-term plan to bring the best innovative therapeutic response to unmet medical needs. Also in November, Cardio3 BioSciences successfully acquired CorQuest and its unique heart access platform that could receive CE marking by the end of The acquisition also included medical devices and implants targeted at mitral valve defects indications. This acquisition bolsters the Company s strategic position as a leading developer of innovative devices for cardiac surgery and the treatment of cardiovascular indications. Moreover, the CorQuest technology platform is fully complementary with Cardio3 BioSciences C-Cath ez and C-Cure programs. Strengthening of operational capabilities with additions to the team At the end of March 2014, the Company announced the appointment of Hanspeter Spek as an Independent director. Mr. Spek represents a major addition to the Board and is expected to contribute significantly to the conclusion of industry partnerships in preparation for the commercialization of the Company s products. Hanspeter was President Global Operations of Sanofi, prior to his retirement from the Company in mid At the beginning of June, the Company appointed Dr. Georges Rawadi as Vice President, Business Development. Leveraging more than 20 years of experience in the healthcare industry, Dr. Rawadi will be responsible for leading Cardio3 BioSciences worldwide business development efforts, by identifying avenues for growth, international expansion and managing the company s business partner relationships. At the beginning of November 2014, Dr. Warren Sherman joined the Company as Chief Medical Officer to support the continued development of the product pipeline, both in cell therapies and cardiovascular diseases.

7 Financial Review On 30 June 2014, the Company completed a capital raise of 25 million, which was priced at 44 per share, a 14% premium to the 30 days average price preceding the transaction. In conjunction with the raise, the Company welcomed new investor Medisun International Limited, a Hong Kong-based investment company. In early July 2014, the Company completed a secondary placement with six Swiss institutional investors. This transaction occurred off-market through an exchange of shares between certain historical shareholders of the Company and Swiss professional investors. The transaction involved the sale of 141,800 shares at 43.5 each. The proportion of shares sold by the existing shareholders did not exceed 25% of their stake in the Company. The share capital and the number of shares of the Company remained unchanged after this secondary transaction. As of 31 December 2014 Cardio3 BioSciences had 30.3 million in treasury compared to 22.1 million on 31 December For the twelve month period ending 31 December 2014, total operating expenses of the Company amounted to 20.9 million compared to 13.0 million for the same period in Increase of operating expenses of 2013 is in line with Company expectations, and partially offset by non-dilutive funding received over 2014, presented as other operating income. At year-end 2014, the net loss for period was 16.5 million versus a net loss of 14.5 million for same period in Cash flow from operating activities represented at year end 2014 a net cash outflow of 17.4 million, or an increase of 6.8 million compared to This increase primarily resulted from the operational costs associated to the C-Cure CHART-1 clinical trial, initiated in mid Cash flow from investing activities represented a net cash outflow amounting to 1.8 million in 2014 mainly due to the acquisition of CorQuest for 1.5 million. In 2013, most of the cash outflow from investing activities resulted from a 3 million investment in a 3-year short term deposit account. Cash flow from financing activities represented a net cash inflow 27.8 million in 2014 compared to 31.6 million in In 2014, the proceeds from issuance of shares amount to 25.3 million (compared to 31.0 million in 2013), whereas the proceeds received from non-dilutive funding (Walloon Region and FP7 programs) amounted to 2.4 million in The complete 2014 Annual Financial Report will be available on the Company s website on May 5, after the Annual Shareholders meeting has taken place.

8 The Company continues to exercise prudent cash management, ending 2014 with 30.3 million in cash and term deposits. Cardio3 management believes that the current cash balance is sufficient to fund the C-Cure clinical program until the availability of the read-out of the primary endpoint, anticipated first half of Significant events occurring post balance sheet date In January 2015, we acquired 100% of the membership interests of Oncyte LLC from Celdara Medical LLC in exchange for a total upfront payment of USD 10 million, comprised of cash consideration of $6 million and new shares of Cardio3 BioSciences for a total value of $4 million. The sales price also includes contingent consideration payments based on future outcome of the research and development until market approval of $50 million and potential additional future sales milestones and royalties. In February 2015, the Company announced that it had successfully raised 32 million through a private placement of ordinary shares to qualified institutional investors in the United States and Europe at a price of per share. The proceeds from the private placement will be used by Cardio3 BioSciences to further develop its newly acquired CAR-T cell technology platform; strengthen the leadership of C-Cure for the treatment of congestive heart failure as well as for general corporate purposes. Auditor report and restatement of 2013 Financial Statements PriceWaterhouseCoopers, the new statutory auditor of the Group has not yet issued its audit report on the annual consolidated accounts for the year ended 31 December The financial statements of the Group of 2013 were restated to reflect errors in the IFRS accounting treatment of respectively the shareholders convertible loans and the share based payments. After due consideration with its auditors, we decided that the shareholders convertible loans should have been accounted for as a financial debt instead of equity (previously called quasi equity ) as originally posted in our 2013 financial statements, because the loans were convertible into a variable number of shares. This correction of error in the IFRS accounting treatment triggers the valuation of this financial debt at fair value at inception and at each subsequent reporting date up till conversion in May The revaluation to fair value of this financial debt led to an additional financial expense of 1.1 million in the 2013 income statement. Due to the conversion of these convertible loans in May 2013, the amount of the financial liability has been reclassified into equity. The adjustment of the share based payments is related to the warrant plan issued by the Group in May 2013, initially valued using a share price at After due consideration, we decided to increase the fair value of the shares used to determine the share based payment measurements to in light of

9 the IPO listing price of 16.65, triggering an increase of the share base payments and an additional noncash expenses in 2013 of 1.0 million. The total net equity of the Group as of 31 December 2013 remains unchanged. These adjustments have no impact on the cash flow statement neither on the net cash position of the Company as of 31 December 2013 as there are a non-cash adjustment. For more information, please contact: Cardio3 BioSciences Christian Homsy, CEO Julie Grade, Corporate Communications Manager Tel: jgrade@c3bs.com For Europe: Consilium Strategic Communications Amber Bielecka, Chris Welsh, Laura Thornton For the U.S: The Ruth Group Lee Roth (Investors), Kirsten Thomas (Media) Tel : To subscribe to Cardio3 BioSciences newsletter, visit Follow us on cardio3@consilium-comms.com Tel: / 7014 lroth@theruthgroup.com kthomas@theruthgroup.com About Cardio3 BioSciences Cardio3 BioSciences is a leader in engineered cell-therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA with the Mayo Clinic (MN, USA) and Dartmouth College (NH, USA). The Company s lead product candidate in cardiology is C-Cure, an autologous stem cell therapy for the treatment of congestive heart failure. The Company s lead product candidate in oncology is CAR-NKG2D, an autologous CAR T-cell product candidate using NKG2D, a Natural Killer (NK) cell receptor designed to target ligands present on most tumor types, including blood cancers and solid tumors. Cardio3 BioSciences is also developing medical devices for enhancing the delivery of bio therapeutic agents into the heart (C-Cath ez ) and for the treatment of mitral valve defects. Cardio3 BioSciences shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD. To learn more about Cardio3 BioSciences, please visit Forward looking statements C3BS-CQR-1, C-Cure, CAR-NKG2D, C-Cath ez, OnCyte, Cardio3 BioSciences and the Cardio3 BioSciences, C-Cath ez, CHART-1, CHART-2 and OnCyte logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the

10 forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of th e plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure and Phase I/IIa clinical trial for CAR-NKG2D additional clinical results validating the use of adult autologous stem cells to treat heart failure and CAR T-cell autologous therapy to treat cancer; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties, competition from others developing products for similar uses, our ability to manage operating expenses, and our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and new business initiatives. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

11 CONSOLIDATED FINANCIAL STATEMENTS AS OF 31 DECEMBER 2014 AND FOR THE YEAR THEN END PREPARED UNDER IFRS AS ENDORSED BY THE EUROPEAN UNION Consolidated statement of comprehensive income ( 000) For the 12 months period ended 31 December (restated) Net sales Manufacturing expenses (5,251) (2,415) Clinical, Quality & Regulatory expenses (7,752) (4,473) Research and Development expenses (2,977) (2,158) General administrative expenses (5,016) (3,972) Other operating income 4, Operating Loss EBIT (16,437) (12,954) Financial income Financial expenses (41) (1,595) Share of Loss of investment accounted for using the equity method (252) - Loss before taxes (16,453) (14,489) Income taxes - - Loss for the period [1] (16,453) (14,489) Losses per share (in ) [2] (2.44) (3.53) Basic and diluted (2.44) (3.53) Other comprehensive lncome

12 Items that will not be reclassified to profit and loss Remeasurements of post employment benefit obligations, net of tax Items that may be subsequently reclassified to profit or loss (154) - (154) - (10) - Currency translation differences (10) - Other comprehensive loss for the year, net of tax (164) - Total comprehensive loss for the year (16,617) (14,489) Total Comprehensive loss for the year attributable to Equity Holders (16,617) (14,489) [1] The restatement of our previously issued consolidated financial statements as of and for the year ended December 31, 2013 relates to changes in our accounting for convertible debentures and the accounting for certain share based payments. [2] Basic and diluted net loss per share are the same in these periods because outstanding warrants would be anti-dilutive due to our net loss in these periods.

13 Consolidated statement of financial position ( 000) As of 31 December (restated) NON-CURRENT ASSETS 11,041 9,783 Intangible assets 10,266 9,400 Property, Plant and Equipment Investment accounted for using the equity method 68 - Other non-current assets CURRENT ASSETS 32,935 22,603 Trade and Other Receivables Grant receivables 1,009 - Other current assets Short term investments 2,671 3,000 Cash and cash equivalents 27,633 19,058 TOTAL ASSETS 43,976 32,386 EQUITY 26,684 16,898 Share Capital 24,615 22,138 Share premium 53,302 30,474 Other reserves 33,763 32,675 Retained loss (84,996) (68,389) NON-CURRENT LIABILITIES 11,239 12,099 Finance leases Advances repayable 10,778 12,072 Other non-current liabilities CURRENT LIABILITIES 6,053 3,389 Finance leases Advances repayable Trade payables 4,042 2,169 Other current liabilities 1, TOTAL EQUITY AND LIABILITIES 43,976 32,386

14 Consolidated statement of cash flows ( '000) For the 12 months period ended 31 December (restated) Net loss) for the year (16,453) (14,489) Non-cash adjustments Depreciation Amortisation Interests on convertible loans Fair value on convertible loans - 1,159 Post Employment Benefit 28 - Share of loss in companies consol. under equity method Gain on contribution IP at incorp. C3BS Asia Ltd. (312) Advances derecognized (507) - Proceeds of grants and advances (2,418) 395 Share-based payments 1,098 1,258 Change in working capital Trade receivables, other receivables (2,048) (452) Trade payables, other payable and accruals 2, Net cash (used)/from in operations (17,414) (10,638) Cash flows from investing activities Acquisitions of Property, Plant & Equipment (590) (73) Acquisitions of Intangible assets (50) (459) Acquisition of short term investments 372 (3,000) Investment in subsidiaries (1,500) - Net cash used in investing activities (1,768) (3,532) Cash flows from financing activities Proceeds from borrowings Repayments of finance leases (138) (163) Proceeds from issuance of shares and exercise warrants net of transactions costs 25,305 30,623 Proceeds from subsidies

15 Proceeds from RCAs & other grants 1, Proceeds from convertible loans Repayment of advances (272) (211) Net cash from financing activities 27,757 31,583 Net cash and cash equivalents at beginning of the period 19,058 1,645 Change in net cash and cash equivalents 8,575 17,413 Net cash and cash equivalents at the end of the period 27,633 19,058

16 Consolidated statement of change in shareholder s equity ( 000 audited) Share capital (Note Error! Reference source not found.) Share premium (Note Error! Referenc e source not Other reserves Retained loss Total Equity found.) Balance as of 1 st January ,138 30,474 32,675 (68,389) 16,898 Capital increase in cash 1,989 23,011-25,000 Exercise of warrants Share-based payments ,098-1,527 Transaction costs associated with capital increases Total transactions with owners, recognized directly in equity - (1,112) - (1,112) 2,477 22,828 1,098-26,403 Loss for the year - - (16,453) (16,453) Currency Translation differences (10) (10) Remeasurements of defined benefit obligation (154) (154) Total comprehensive loss for the year (10) (16,607) (16,617) Balance as of 31 December ,615 53,302 33,763 (84,996) 26,684